Quantcast
Home > Quotes > ONCT

Oncternal Therapeutics, Inc. Common Stock (ONCT) Quote & Summary Data

ONCT 
$6.94
*  
0.26
3.61%
Get ONCT Alerts
*Delayed - data as of Jun. 25, 2019  -  Find a broker to begin trading ONCT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ONCT After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 6 / $ 7.92
1 Year Target
10.496
Today's High / Low
$ 7.20 / $ 6.70
Share Volume
19,638
50 Day Avg. Daily Volume
205,788
Previous Close
$ 7.20
52 Week High / Low
$ 25.60 / $ 0.74
Market Cap
23,845,660
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Jun. 10, 2019
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
19,638
50 Day Avg. Daily Volume:
205,788

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -9.03

Trading Range

The current last sale of $6.94 is 837.84% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 7.20 $ 25.60
 Low: $ 6.70 $ 0.74

Company Description (as filed with the SEC)

We are a biopharmaceutical company dedicated to the discovery, development and commercialization of medicines to treat serious and/or significant unmet medical conditions. Under an exclusive worldwide license agreement with the University of Tennessee Research Foundation, or UTRF, we are developing UTRF's proprietary selective androgen receptor degrader, or SARD, technology, which we believe has the potential to provide compounds that can degrade or antagonize multiple forms of androgen receptor, or AR, thereby potentially inhibiting tumor growth in patients with progressive castration-resistant prostate cancer, or CRPC, including those patients who do not respond to or are resistant to current androgen targeted therapies.  ... More ...  



Risk Grade

Where does ONCT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.10
Open Date:
Jun. 25, 2019
Close Price:
$ 6.94
Close Date:
Jun. 25, 2019


Consensus Recommendation

Analyst Info